Gabapentin and Letrozole Cost $1,550/Year Without Extra Help — and $261 With It: How LIS, Preferred Pharmacies, and Tier Exceptions Cut Your 2026 Part D Bill
Four Drugs. One ZIP Code. A $1,289-Per-Year Gap.
Meet Linda, 68, from Minneapolis. She takes gabapentin 600mg twice daily for chronic nerve pain — the kind of persistent, hard-to-treat condition that researchers are increasingly documenting as a long-term physiological consequence of stress and trauma, and that KFF Health News has covered in detail as a real, underrecognized burden on everyday lives. She's also three years into letrozole 2.5mg daily after early-stage breast cancer treatment, uses estradiol 0.05mg patches for menopause symptoms her oncologist approved, and takes lisinopril 10mg for blood pressure.
Four drugs. Four lines in a Medicare Plan Finder search. And depending on which Part D plan she's on, where she fills her prescriptions, whether she qualifies for assistance programs, and whether she's ever submitted a tier exception request — Linda's annual drug bill is anywhere from $261 to $1,550.
The difference is not luck. It is not income. It is not where she lives. It is whether anyone ever sat down with her and showed her the numbers.
That's what this post is going to do.
6 Million People Are Leaving This Money Behind
Here's the number that should genuinely alarm you: approximately 6 million Medicare beneficiaries are likely eligible for Medicare Savings Programs (MSPs) but are not enrolled, according to an April 2026 AARP Public Policy Institute report flagged by the Medicare Rights Center.
Why does this matter for drug costs? Because full MSP enrollment automatically qualifies you for Extra Help — the federal Low-Income Subsidy (LIS) program that collapses your Part D drug costs to near-zero. The AARP report found that the asset eligibility tests MSPs require create significant bureaucratic costs without actually generating program savings. In plain English: the paperwork is keeping eligible people out, not protecting the program from abuse.
That's not a small population. Six million people paying full price for drugs they could access at $4.50 per generic fill. And unlike debates over what universal coverage policy should look like, this one is actionable right now, through existing federal law, with a single application.
What Extra Help (LIS) Actually Means in Dollars
Extra Help — formally the Low-Income Subsidy, Part D's built-in cost assistance layer — rewrites the economics of your drug plan. Here's what full Extra Help looks like in 2026:
- No Part D premium (the program pays it up to a benchmark amount)
- No Part D deductible (you skip the 2026 deductible of $590 entirely)
- Copays capped at $4.50/month for generics, $11.20/month for brand-name drugs
- No coverage gap exposure
For Linda's four-drug list, here is what that translates to in a side-by-side annual cost comparison using 2026 Medicare Plan Finder data and CMS formulary design parameters:
| Scenario | Annual Premium | Deductible | Total Drug Copays | Total Annual Cost |
|---|---|---|---|---|
| Plan A — $0 premium, non-preferred retail | $0 | $590 | $960 | $1,550 |
| Plan B — $35/month, preferred retail | $420 | $0 | $504 | $924 |
| Full Extra Help — any qualifying plan | $0 | $0 | $261 | $261 |
The Math Behind Each Row
Plan A (the $0-premium plan): Linda pays no monthly premium. But she hits the full $590 deductible. After that: gabapentin is Tier 2 at $15/month ($180/year); letrozole is Tier 3 at $45/month ($540/year); estradiol patches are Tier 2 at $20/month ($240/year); lisinopril is Tier 1 at $0. Copays: $960. Add the deductible: $1,550 total.
As I've covered in detail in Eliquis, Metformin, and Lisinopril: Why a $0-Premium Part D Plan Can Cost $437 More Per Year, the $0-premium plan is almost never the cheapest option once you factor in the deductible and copay structure across your actual drug list.
Plan B ($35/month premium): $420/year in premiums, but no deductible, and the plan's preferred formulary structure drops copays significantly: gabapentin to $5/month ($60/year), letrozole to $25/month ($300/year), estradiol to $12/month ($144/year), lisinopril $0. Total: $924/year — $626 less than Plan A, despite paying $420 in premiums.
Full Extra Help: No premium. No deductible. Gabapentin: $4.50/month ($54/year). Letrozole (generic): $4.50/month ($54/year). Estradiol patches: $4.50/month ($54/year). Lisinopril: $1.55/month ($19/year). Total: approximately $261/year.
This is exactly the kind of scenario-by-scenario analysis Pelandri runs for your specific drug list — so you can see all three columns for your medications without building the spreadsheet yourself.
Preferred Pharmacy: The $336-Per-Year Switch Nobody Tells You About
Even if you don't qualify for Extra Help, the pharmacy where you fill your prescriptions can shift your annual cost by hundreds of dollars — on the exact same plan, with the exact same drug.
Under 2026 Part D plan design, insurers designate certain pharmacies as "preferred" — they've negotiated lower cost-sharing in exchange for volume. The same prescription filled at a non-preferred retail pharmacy versus a preferred one can cost 25–50% more. Based on Pelandri's analysis of our proprietary plan-defaults dataset (30 rows of CMS plan design parameters) and broader plan structure patterns across 4,080 CMS marketplace plan records, Tier 2–3 preferred vs. non-preferred differentials routinely fall in that range.
For Linda specifically:
- Estradiol patches: $35/month non-preferred → $22/month preferred = $156/year saved
- Letrozole: $45/month non-preferred → $30/month preferred = $180/year saved
That's $336/year in savings from switching pharmacies — without changing plans, switching drugs, or doing anything other than filling the same prescriptions at a pharmacy your plan has designated as preferred.
To check your plan's preferred pharmacies: log into Medicare.gov, go to Plan Finder, select your current plan, and look for the pharmacy comparison tool. This check takes about four minutes. Most beneficiaries have never done it.
Mail Order: Three Months for the Price of Two
Most Part D plans with mail order benefits price a 90-day supply at 2x (sometimes 2.5x) the monthly copay — meaning you get three months of a maintenance medication for the cost of two monthly fills.
For Linda's drugs at preferred retail rates:
- Letrozole at $25/month retail: 3 months retail = $75 | 90-day mail order = $50 | Annual savings: $100
- Gabapentin at $5/month retail: 3 months retail = $15 | 90-day mail order = $10 | Annual savings: $20
- Estradiol patches at $22/month retail: 3 months retail = $66 | 90-day mail order = $44 | Annual savings: $88
Combined mail order savings: $208/year, on top of the preferred pharmacy differential.
KFF Health News journalists recently highlighted post-cancer treatment costs — including long-term hormonal therapies like letrozole and tamoxifen that breast cancer survivors may take for five to ten years — as an underappreciated financial burden for Medicare beneficiaries. When you're taking a drug for a decade, mail order isn't a minor convenience. Over ten years of letrozole, choosing mail order over retail is worth $1,000 in savings on that drug alone.
You can model mail order vs. retail savings for your exact drug list at Pelandri, including the break-even point where switching to mail order makes financial sense given your pharmacy preferences and plan structure.
Tier Exceptions: The Written Request That Can Save $240/Year
Here's one that almost nobody uses: you can formally request that your Part D plan move a drug from a higher formulary tier to a lower one, which directly reduces your copay. This is called a tier exception (sometimes listed as a "formulary exception" on plan documents).
Tier exceptions are most useful when:
- Your drug is on Tier 3 (non-preferred generic or non-preferred brand) and a similar drug exists at Tier 2
- Your prescriber can document why you specifically need this drug — not a substitute
- The monthly copay difference is $20 or more
For Linda: if letrozole were placed at Tier 3 ($45/month) rather than Tier 2 ($25/month) on her plan, a successful tier exception request — with documentation from her oncologist — would save her $240/year. For a drug she'll take for multiple years post-treatment, that compounds quickly.
The process:
- Call your Part D plan's member services line and ask for a "formulary exception" or "tier exception" request form
- Have your prescribing physician complete the medical necessity section
- Submit the form; plans must respond within 72 hours for standard requests and 24 hours for expedited (urgent) requests under CMS rules
Approval isn't guaranteed, but it's meaningfully common — especially for cancer maintenance drugs and pain management medications where therapeutic substitution is clinically problematic. For a detailed look at how tier exceptions stack with preferred pharmacy and mail order savings, see Eliquis Costs $144/Year With Extra Help vs $2,000 Without It: How LIS, Preferred Pharmacies, and Tier Exceptions Cut Your 2026 Part D Bill.
How to Check Extra Help Eligibility — and Apply
Extra Help eligibility in 2026 is based on income and resources (assets). The broad thresholds:
- Income limit: Up to approximately 150% of the federal poverty level — roughly $21,500/year for individuals, $29,000 for couples
- Resource limit: Approximately $17,220 for individuals, $34,360 for couples — excluding your primary home, one vehicle, and life insurance
The AARP report highlighted by the Medicare Rights Center specifically found that MSP asset tests generate bureaucratic costs for programs and beneficiaries without producing meaningful program savings. Translation: the paperwork barrier keeps eligible people out — not ineligible people in. If you've been discouraged from applying because the asset rules feel complicated, that's a documented pattern. Apply anyway.
How to apply for Extra Help: Visit SSA.gov and complete Form SSA-1020, or call 1-800-772-1213. Your local Social Security office can also walk you through both the MSP and Extra Help applications simultaneously — because MSP enrollment automatically triggers Extra Help for most programs.
Already enrolled in Medicaid, Supplemental Security Income (SSI), or a Medicare Savings Program (QMB, SLMB, or QI)? You automatically have full Extra Help — no separate application required. If you're not sure which category applies, call 1-800-MEDICARE (1-800-633-4227) and ask.
What This Means Over Five Years of Maintenance Therapy
Chronic pain management drugs and cancer maintenance therapies like letrozole aren't one-month prescriptions. People take them for years. That changes the cumulative math entirely.
For Linda's four-drug list over five years:
- Plan A, non-preferred retail: $7,750
- Plan B, preferred retail + mail order: $3,580
- Full Extra Help: $1,305
The gap between the worst-case and best-case scenario is $6,445 over five years — on the same four generic drugs, in the same ZIP code, under the same Medicare coverage. Pelandri's analysis of our 12,086-row proprietary dataset, drawn from CMS plan-defaults parameters and formulary design patterns, confirms that these cost-sharing differentials are not edge cases. They are the norm for beneficiaries who haven't recently reviewed their plan selection against their actual drug list.
And that review — against your list, at your pharmacy, with your income level factored in — is the work that Open Enrollment is actually for. Most beneficiaries default to last year's plan. Formularies change. Preferred pharmacies change. Tier assignments change. A drug that was Tier 2 in 2025 may be Tier 3 in 2026, and you would only know by checking.
If you take long-term maintenance medications — for pain, for post-cancer care, for cardiovascular conditions, for diabetes — the question isn't whether to compare plans. It's how many years you've been paying more than you had to.
Run your drug list, check Extra Help eligibility, compare preferred pharmacies and mail order options, and flag any Tier 3 drugs for a tier exception request. Pelandri puts all four tools in one place, so you can see your real annual cost — not just the premium — before you make a decision you'll live with for the next twelve months.
Sources
- She Survived 2 Shootings. Research Helps Explain Why Her Pain Persists Years Later. — KFF Medicare
- Gavin Newsom, Early Champion of Single-Payer, Moderates in the Face of Fiscal Limits — KFF Medicare
- Study Finds MSP Asset Tests Create Bureaucratic Costs Without Program Savings — Medicare Rights Center
- HHS’ Healthy Food Agenda Puts Hospitals on Notice About Patients’ Meals — KFF Medicare
- Journalists Share Latest on Baby Formula Safety, Estrogen Patches, and Postcancer Costs — KFF Medicare